Lilly Says Its New Obesity Pill Beat High-Dose Oral Semaglutide — But The Comparison Has A Catch
Lilly’s Foundayo Comes Out Ahead Of High-Dose Oral Semaglutide In New Diabetes Analysis
The New Battle For The Weight-Loss Pill Market
The result looks simple. The evidence behind it is more complicated.
Eli Lilly says its once-daily GLP-1 pill Foundayo produced greater weight loss and better blood-sugar control than a 25 mg dose of oral semaglutide in adults with type 2 diabetes.
At 52 weeks, the company’s primary indirect comparison associated Foundayo 17.2 mg with 1.5 percentage points more body-weight loss and a 0.3 percentage-point greater reduction in A1C than oral semaglutide 25 mg.
That gives Lilly another potentially useful result in the rapidly expanding market for oral GLP-1 medicines.
It does not, however, mean a randomised head-to-head trial has proved Foundayo is the better drug at those doses. The analysis compared data drawn from two different clinical trials. That distinction matters.
What Lilly’s New Analysis Found
The comparison centred on Foundayo, the brand name for orforglipron, and a higher 25 mg dose of oral semaglutide.
Lilly said that after adjusting for factors including age, sex, baseline body weight and starting A1C, the 17.2 mg Foundayo group showed 1.5 percentage points more weight loss than the 25 mg semaglutide group at 52 weeks.
The estimated difference in A1C was 0.3 percentage points in Foundayo’s favour.
Alternative statistical methods produced a range of results. Across those analyses, Lilly said Foundayo was associated with between 1.5 and 2.4 percentage points greater weight loss and between 0.3 and 0.6 percentage points greater A1C reduction.
That consistency strengthens the signal, but it does not erase the core limitation: the patients were not randomised directly between Foundayo 17.2 mg and oral semaglutide 25 mg inside the same trial.
Why This Was Not A True Head-To-Head Test
A direct randomised trial is usually the cleanest way to compare two medicines.
Patients are enrolled under the same protocol, treated over the same period and assessed using the same procedures. Randomisation helps reduce the risk that differences in patient characteristics distort the result.
That did happen previously with lower semaglutide doses.
In the Phase 3 ACHIEVE-3 study, 1,698 adults with type 2 diabetes inadequately controlled with metformin were randomised to receive either 9 mg or 17.2 mg orforglipron, or 7 mg or 14 mg oral semaglutide.
At 52 weeks, the higher Foundayo dose lowered A1C by an average of 2.2 percentage points, compared with 1.4 percentage points for oral semaglutide 14 mg.
Average weight loss was also greater. Participants on 17.2 mg Foundayo lost 9.2 per cent of body weight, compared with 5.3 per cent for the 14 mg semaglutide group.
The new 25 mg comparison goes beyond that trial.
Instead of randomising patients directly between those two doses, Lilly used data from ACHIEVE-3 and compared them statistically with results from PIONEER PLUS, a separate Phase 3b study of higher-dose oral semaglutide.
That technique can be informative when direct evidence does not exist. It is still one step removed from putting both medicines into the same trial.
For readers trying to judge medical headlines, the distinction is similar to the broader problem described in why a new headline is not always a new discovery: the evidence type matters as much as the headline result.
What PIONEER PLUS Actually Tested
PIONEER PLUS enrolled 1,606 adults with type 2 diabetes and compared oral semaglutide doses of 14 mg, 25 mg and 50 mg.
The study showed that the higher doses produced larger reductions in A1C and body weight than the 14 mg dose.
At 52 weeks, average A1C fell by 1.8 percentage points with 25 mg oral semaglutide and by 2.0 percentage points with 50 mg, compared with 1.5 percentage points with 14 mg.
The trial was not designed to compare semaglutide with Foundayo.
Lilly’s new analysis therefore tries to bridge two separate datasets and estimate how the 17.2 mg Foundayo group would compare with the 25 mg oral semaglutide group after adjusting for measured differences.
That is useful evidence.
It is not the same as direct evidence.
Why Calling This An “Obesity Pill” Can Be Misleading
Foundayo is an obesity medicine in the United States.
It was approved in April 2026 for adults with obesity, or adults with overweight who also have at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity.
But the comparison announced on 29 September was conducted using data from adults with type 2 diabetes.
That matters because weight-loss responses in people with type 2 diabetes can differ from those seen in obesity trials involving people without diabetes.
The safest reading is therefore narrow: among the populations represented in these diabetes trials, Lilly’s indirect analysis favoured Foundayo 17.2 mg over oral semaglutide 25 mg on weight and A1C outcomes.
It should not automatically be converted into the broader claim that Foundayo has proved superior for obesity treatment in the general population.
Foundayo’s Practical Advantage Is Bigger Than A Single Number
Foundayo is a small-molecule GLP-1 receptor agonist taken once a day.
Unlike peptide-based oral semaglutide formulations, Foundayo can be taken with or without food and does not require a fasting period or a tightly controlled amount of water.
That may sound minor beside weight-loss percentages, but administration matters in real life.
A drug that is easier to take correctly may be easier for some patients to use consistently. Convenience, tolerability, price, access and long-term adherence can all matter alongside trial efficacy.
This is part of the larger shift created by GLP-1 medicines and their growing effect on consumer behaviour. The market is no longer defined by one injectable medicine. It is becoming a contest between injections, daily pills and increasingly sophisticated combinations.
The Safety Picture Still Matters
Foundayo is not a casual weight-loss supplement.
Its U.S. prescribing information includes warnings and precautions covering pancreatitis, severe gastrointestinal reactions, dehydration that can contribute to kidney injury, hypoglycaemia when used with certain diabetes medicines, gallbladder problems and other risks.
The medicine is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.
Common adverse effects include nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain.
Those details matter because a small efficacy advantage does not, by itself, decide which treatment is appropriate for an individual patient.
Treatment decisions depend on the full clinical picture.
Why Lilly And Novo Nordisk Care So Much About Oral GLP-1 Drugs
The next phase of the obesity-drug market is not only about producing greater average weight loss.
It is also about removing friction.
Weekly injections have already turned GLP-1 medicines into some of the most commercially important drugs in the world. A powerful pill could expand the pool of patients willing to start treatment, simplify distribution and potentially make manufacturing easier to scale.
That is why higher-dose oral semaglutide and Foundayo matter even when injectable medicines remain highly effective.
The competition is moving towards a world in which patients may choose between multiple oral and injectable options with different trade-offs in efficacy, dosing, tolerability and convenience.
What The Result Does — And Does Not — Prove
The strongest conclusion is also the simplest.
Lilly now has an indirect analysis in adults with type 2 diabetes suggesting that Foundayo 17.2 mg can produce greater weight loss and A1C reduction than oral semaglutide 25 mg at 52 weeks.
It also has direct Phase 3 evidence showing Foundayo outperforming oral semaglutide at lower 7 mg and 14 mg comparator doses.
Together, those findings strengthen Lilly’s competitive case.
What they do not provide is a randomised Foundayo 17.2 mg versus oral semaglutide 25 mg head-to-head trial.
That missing trial is important because indirect comparisons depend on statistical adjustment and assumptions about whether populations and study conditions are sufficiently comparable.
The result is therefore meaningful, but it should be read as evidence of an advantage rather than the final word.
The oral GLP-1 contest is becoming one of the most important battles in obesity and diabetes medicine. The next decisive step will be stronger direct evidence showing how the leading pills perform when they face each other under the same conditions.
Sources
Eli Lilly and Company — Foundayo 17.2 mg versus oral semaglutide 25 mg indirect treatment comparison — Primary company release detailing the 29 September 2026 analysis, ACHIEVE-3 results and methodology.
U.S. Food and Drug Administration — Foundayo prescribing information — Official indication, dosing, contraindications, warnings and adverse-reaction information.
PubMed — PIONEER PLUS: oral semaglutide 25 mg and 50 mg versus 14 mg — Published Phase 3b trial data used in the indirect comparison.
Next Reads
The Ozempic Effect: How Weight-Loss Drugs Are Shrinking Food Demand — A wider look at how GLP-1 adoption is already changing spending and food demand.
Why Old Science Suddenly Looks New In Your News Feed — A guide to distinguishing a genuinely new result from a new analysis or recycled headline.
Why A Treatment That Works In Mice Can Still Fail In Humans — A broader explainer on why study design and evidence stage matter when judging treatment claims.
